Why Are Dialysis Provider Stocks Trading Higher On Tuesday?

Tuesday, Novo Nordisk A/S NVO released the headline results from the kidney outcomes trial, FLOW. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression as well as cardiovascular and kidney death of 24% for people…#novonordiskasnvo #davitaincdva #novonordisk #novonordisks #ozempic #fresenius #davita #glp1 #ozempicandwegovy #citi
Source: Reuters: Health - Category: Consumer Health News Source Type: news